The aim of the project is to further develop and optimize the OncoCDx companion diagnostic platform through its integration with a dedicated in-house next-generation sequencing (NGS) facility. The project will focus on implementing advanced molecular profiling workflows and integrated bioinformatics tools to enable comprehensive characterization of tumor samples and the identification of predictive biomarkers associated with response to cancer immunotherapy.

The integration of the OncoCDx platform with high-throughput sequencing technologies will significantly enhance the sensitivity, scope, and efficiency of molecular diagnostics while reducing turnaround time for clinically actionable results. This approach will facilitate the translation of genomic insights into clinical decision-making and support physicians in selecting the most appropriate immunotherapeutic strategies for individual patients.

As a result, the project will deliver an advanced companion diagnostic platform enabling the implementation of precision oncology approaches in clinical practice. Ultimately, the project is expected to improve patient stratification, optimize treatment selection, and contribute to better clinical outcomes for cancer patients receiving immunotherapy.

2024 - 2027

Project value: Big Pharma Confidential Industrial Agreement (CIA)

2022 - 2023

Grant number: Q4425779

EU contribution: 174 140,93 €

A paradigm shift in oncology is represented by immune checkpoint inhibitors; however, clinical efficacy remains constrained by complex resistance mechanisms. In this project, advanced AI modeling is integrated with multi-omic data to transcend the limitations of current monogenic biomarkers.

Genomic and transcriptomic profiling are leveraged to decode the synergistic interplay between tumor neoantigens and the immune microenvironment. Through the identification of multidimensional signatures of immune response, high-fidelity companion diagnostics are being developed, designed to personalize patient care.

2020 - 2022

Project value: Big Pharma Confidential Industrial Agreement (CIA)

2019 - 2020

Grant number: 28296

Project value: £ 200,000